NCT05923905View on ClinicalTrials.gov

Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients

PHASE4RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

January 18, 2023

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Sporadic and Familial Amyotrophic Lateral Sclerosis
Interventions
DRUG

FB1006

30mg/day

DRUG

Placebo

30mg/day

Trial Locations (1)

100191

RECRUITING

Peking University Third Hospital, Beijing

All Listed Sponsors
lead

Peking University Third Hospital

OTHER